Latest News about BLUE
Recent news which mentions BLUE
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
November 15, 2024
From Benzinga
Earnings Scheduled For November 14, 2024
November 14, 2024
From Benzinga
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
October 11, 2024
From Benzinga
The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts
September 25, 2024
Tickers
BLUE
From Benzinga
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
September 24, 2024
From Benzinga
From Benzinga
From InvestorPlace
From Benzinga
Better Buy: Bluebird Bio Vs. Novavax
April 13, 2024
From Motley Fool
Tickers
BLUE
From Motley Fool
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 26, 2024
From Benzinga
Earnings Scheduled For March 26, 2024
March 26, 2024
From Benzinga
Why Bluebird Bio Stock Flew Higher Than the Market Today
March 18, 2024
From Motley Fool
Why Bluebird Bio Stock Dived Into the Red on Tuesday
March 05, 2024
From Motley Fool
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
From Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
From Benzinga
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
January 27, 2024
Tickers
BLUE
From Motley Fool
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
From Benzinga
2 Red Flags for Bluebird Bio Stock
January 10, 2024
From Motley Fool
Better Risky Investment: Bluebird Bio vs. Shiba Inu
January 03, 2024
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
